Status:
RECRUITING
PET/CT Whole-body Dynamic Acquisition at FDG to Metastatic Melanoma Under Immunotherapy
Lead Sponsor:
University Hospital, Brest
Conditions:
Metastatic Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
The value of 4D body-to-whole dynamic acquisition in FDG PET / CT to differentiate progression / pseudo-progression during the first therapeutic assessment (PET1) of metastatic melanoma treated with i...
Eligibility Criteria
Inclusion
- Patient old ≥ 18 years
- With metastatic melanoma
- Treated with anti-PD1 : Nivolumab or Pembrolizumab or Combo IPI-Nivo
- Having formulated a non-opposition
Exclusion
- \- Minor patient \< 18 years
- Pregnancy or breastfeeding
- Other type of tumor than metastatic melanoma
- Non-eligibility for the examination
- Refusal of participation
Key Trial Info
Start Date :
June 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
June 26 2026
Estimated Enrollment :
56 Patients enrolled
Trial Details
Trial ID
NCT04272658
Start Date
June 26 2020
End Date
June 26 2026
Last Update
June 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Hospital University ff Brest
Brest, Finistere, France, 29200